Literature DB >> 3408645

Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.

M A Smith1, S Merry, J G Smith, S B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3408645      PMCID： PMC2246452          DOI： 10.1038/bjc.1988.131

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  21 in total

1.  Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors:  A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

2.  Phase I study of vinblastine and verapamil given by concurrent iv infusion.

Authors:  A B Benson; D L Trump; J M Koeller; M I Egorin; E A Olman; R S Witte; T E Davis; D C Tormey
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

3.  Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.

Authors:  J C Yalowich; J R Zucali; M Gross; W E Ross
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

4.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.

Authors:  J C Yalowich; W E Ross
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

6.  Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors:  L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

7.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

8.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.

Authors:  A Ramu; R Spanier; H Rahamimoff; Z Fuks
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

10.  Occurrence of a multidrug-resistant phenotype in human lung xenografts.

Authors:  J Mattern; M Bak; M Volm
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640
View more
  4 in total

1.  Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.

Authors:  S Oudard; A Thierry; T J Jorgensen; A Rahman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.

Authors:  F W Busch; U Schmittele; G Ehninger
Journal:  Blut       Date:  1990-04

3.  Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin.

Authors:  K E Woods; S Grant; S Yanovich; D A Gewirtz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance.

Authors:  Jianjun Wang; Guojun Li
Journal:  Oncol Lett       Date:  2014-12-05       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.